Ischemic Stroke after Bivalent COVID-19 Vaccination: A Self-Controlled Case

Series Study

Stanley Xu, PhD^{1,2}; Lina S. Sy, MPH¹; Vennis Hong, MPH¹; Kimberly J. Holmquist, MPH¹; Lei Qian, PhD¹; Paddy Farrington, PhD³; Katia J. Bruxvoort, PhD^{1,4}; Nicola P. Klein, MD, PhD⁵; Bruce Fireman, MA⁵; Bing Han, PhD¹; Bruno J. Lewin, MD¹

¹Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California

²Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA

³School of Mathematics and Statistics, The Open University, Milton Keynes, UK

⁴Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Al 35233

⁵Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland, California

Corresponding author: Stanley Xu, PhD Department of Research & Evaluation Kaiser Permanente Southern California 100 S Los Robles Pasadena, California 91101 Tel: (626) 564-3958 Email: <u>Stan.Xu@kp.org</u>

Word Count: 3,387

Tables: 4 Tables

Figure: 1 Figure

Supplement: eTable 1, eTable 2, eTable3

Abstract

Introduction The potential association between bivalent COVID-19 vaccination and ischemic stroke remains uncertain, despite several studies conducted thus far. The purpose is to evaluate the risk of ischemic stroke following bivalent COVID-19 vaccination.

Methods A self-controlled case series study was conducted among members aged ≥12 years who experienced ischemic stroke between September 1, 2022 and March 31, 2023 in a large California health care system. Ischemic strokes were identified using ICD-10 codes in Emergency Department and inpatient settings. Exposures were Pfizer-BioNTech or Moderna bivalent COVID-19 vaccination. Risk intervals were pre-specified as 1–21 days and 1–42 days after bivalent COVID-19 vaccination; all non-risk-interval person-time served as control interval. We conducted overall and subgroup analyses by age, history of SARS-CoV-2 infection, and co-administration of influenza vaccine. When an elevated risk was detected, we performed chart review of ischemic strokes, and re-evaluated the risk.

RESULTS With 4933 cases, we found no increased risk within 21-day risk interval across vaccines and by subgroups. However, an elevated risk emerged within 42-day risk interval among individuals <65 years who received co-administration of Pfizer-BioNTech bivalent vaccine and influenza vaccine on the same day; relative incidence (RI) was 2.14 (95% CI, 1.02–4.49). Among those who also had history of SARS-CoV-2 infection, RI was 3.94 (95% CI, 1.10–14.16). After chart review, RIs were 2.35 (95% CI, 0.98–5.65) and 4.33 (95% CI, 0.98–19.11), respectively. Among individuals <65 years who received Moderna bivalent vaccine and had history of SARS-CoV-2 infection, RI

was 2.62 (95% CI, 1.13–6.03) before chart review and 2.24 (95% CI, 0.78–6.47) after chart review.

CONCLUSIONS The potential association between bivalent COVID-19 vaccination and ischemic stroke in the 1-42-day analysis warrants further investigation among individuals <65 years with influenza vaccine co-administration and prior SARS-CoV-2 infection.

Keywords: ischemic stroke; bivalent COVID-19 vaccine; influenza vaccine; selfcontrolled case series; co-administration

Introduction

On August 31, 2022, the U.S. Food and Drug Administration (FDA) granted emergency use authorizations (EUAs) for the Pfizer-BioNTech bivalent COVID-19 vaccine for individuals aged 12 years and older and the Moderna bivalent COVID-19 vaccine for individuals aged 18 years and older.^{1,2} The bivalent vaccines contain mRNA components derived from both the original strain of SARS-CoV-2 and the omicron variant BA.4 and BA.5 sublineages. Designed to be administered as a single booster dose, bivalent COVID-19 vaccines were recommended to be given \geq 60 days after either primary vaccination or a monovalent booster dose.² In the context of waning protection from primary vaccination, bivalent vaccines enhanced the immune response and

boosted protection against the virus, offering an additional layer of defense for previously-vaccinated individuals.³⁻⁵

Safety data for bivalent mRNA COVID-19 vaccines were initially limited. Because the chemical components and production processes between monovalent and bivalent vaccines were similar, FDA granted EUAs for the bivalent COVID-19 vaccines based on safety data for monovalent vaccines as well as limited bivalent safety data from clinical trials.^{1,2} To monitor safety post-licensure, a study utilizing v-safe and the Vaccine Adverse Event Reporting System (VAERS) examined bivalent booster vaccinations in individuals aged \geq 12 years and found that the safety profile was similar to that described for monovalent booster vaccinations.⁶ A recent study which comprehensively assessed potential adverse events associated with bivalent vaccines using TreeScan in the Vaccine Safety Datalink (VSD) network found no increased risk for a broad range of adverse events.⁷

The VSD has monitored COVID-19 vaccine safety since vaccinations began in December 2020.⁸ In late 2022, VSD's rapid cycle analyses (RCA) detected a safety signal for ischemic stroke following the Pfizer-BioNTech COVID-19 bivalent booster vaccination among those 65 years and older, particularly among those who had received a bivalent booster dose and a high-dose or adjuvanted influenza vaccine on the same day (co-administration).⁹ The CDC and FDA announced this safety signal in January 2023.¹⁰ This safety signal attenuated as data accumulated.¹¹ Another cohort study among adults aged 65 and older reported that those who received the Pfizer-BioNTech bivalent booster had a similar hazard for ischemic stroke encounters compared to those who received the Moderna bivalent booster vaccine, but had a lower

hazard than those who received the Pfizer-BioNTech /Moderna monovalent boosters.¹² In another study, compared to monovalent vaccination, bivalent vaccination was not found to be associated with increased risk of ischemic stroke, hemorrhagic stroke, myocardial infarction, and pulmonary embolism.¹³

The objective of this study was to assess the risk of ischemic stroke after bivalent COVID-19 vaccination among individuals enrolled in Kaiser Permanente Southern California (KPSC) using a modified self-controlled case series (SCCS) design. Subgroup analyses were also conducted by age (<65 years versus ≥65 years), history of SARS-CoV-2 infection, and co-administration of influenza vaccine.

Methods

Study Population and Study Period

We conducted a SCCS study among members aged \geq 12 years from KPSC, a large integrated health care system in the US. The SCCS analytic datasets included individuals who experienced ischemic stroke events between September 1, 2022 and March 31, 2023, had completed a COVID-19 vaccine primary series, and had received their last monovalent dose \geq 60 days before September 1, 2022. We required KPSC membership on September 1, 2022.

Exposure and Observation Period

The exposure was defined as the administration of the Pfizer-BioNTech bivalent COVID-19 vaccine (for individuals aged ≥12 years) or the Moderna bivalent COVID-19 vaccine (for individuals aged ≥18 years) between September 1, 2022 and March 31, 2023. The observation period for the recipients of a bivalent COVID-19 vaccine started on September 1, 2022 and ended on March 31, 2023 or upon death, receipt of the second bivalent dose, or disenrollment, whichever came first.

To adjust for seasonality, we also included ischemic stroke events occurring among eligible individuals aged \geq 12 years who had completed a primary series and had received their last monovalent dose \geq 60 days before September 1, 2022, but who did not receive a bivalent vaccine during September 1, 2022 - March 31, 2023 (non-bivalent recipients [NBR]). The observation period for ischemic stroke events among NBR started on September 1, 2022, and ended on March 31, 2023, or upon death or disenrollment, whichever came first.

Outcome

The outcome was defined as the first occurrence of an ischemic stroke event between September 1, 2022 and March 31, 2023.¹⁴ Ischemic stroke events were identified through medical encounters with an ICD-10 diagnosis code of G45.8, G45.9, or I63.* in the emergency department (ED) or inpatient settings. We also looked back 30 days prior to September 1, 2022, to ensure that the episode was incident. We excluded ischemic stroke events due to other possible causes and adjusted the onset date (details in eTable 1).

We considered these ischemic stroke events that were identified with ICD-10 codes to be electronically identified ischemic stroke events.

Covariates

We collected demographic variables (age, sex, race/ethnicity) to describe the characteristics of the study population, as well as concomitant influenza vaccination

during the study period and history of SARS-CoV-2 infection in the year prior to September 1, 2022.

Statistical Analyses

We assessed the risk of ischemic stroke following the administration of the Pfizer-BioNTech and Moderna bivalent COVID-19 vaccines separately. Demographic characteristics of individuals who experienced ischemic stroke events during the study period were described among Pfizer-BioNTech bivalent vaccine recipients, Moderna bivalent vaccine recipients, and NBR.

The risk intervals were pre-specified as 1–21 days and 1–42 days after administration of bivalent COVID-19 vaccines, with person-time outside of these risk intervals serving as the control interval. The risk intervals started on the day of vaccination (Day 1). Because individuals who had ischemic stroke events might be likely to postpone or avoid bivalent vaccination, we used a modified SCCS approach for event-dependent exposures.¹⁷ The modified SCCS used a pseudo-likelihood approach in the counterfactual framework to estimate relative incidence (RI) and 95% confidence intervals (CI) of events comparing the risk intervals to their corresponding control intervals by maximizing a Poisson pseudo-likelihood. In the SCCS analyses, ischemic stroke events occurring among eligible individuals who did not receive the bivalent vaccines were included to account for seasonality, by incorporating calendar month into the model.¹⁴ Given that age did not significantly vary during the relatively short observation period of 7 months, it was not adjusted as a time-varying covariate.

Additionally, we performed several subgroup analyses based on age (<65 versus \geq 65 years), co-administration of bivalent COVID-19 vaccine with same-day influenza vaccine (yes/no), and history of SARS-CoV-2 infection (confirmed by a positive laboratory test or a COVID-19 diagnosis) within one year prior to September 1, 2022. When a safety signal (i.e., the lower bound of the 95% CI for RI exceeded 1.0) was detected in analyses of electronically identified ischemic stroke events, we conducted chart review among recipients of bivalent COVID-19 vaccines to confirm ischemic stroke events and identify onset date to determine whether confirmed ischemic stroke events fell in the risk or control interval; confirmation rates were then calculated (number of confirmed events divided by number of electronically identified events reviewed). We did not conduct chart review on ischemic stroke events among NBR due to the large number of events in this group and limited resources. In analyses of confirmed ischemic stroke events among recipients of bivalent COVID-19 vaccines, we introduced a randomized allocation of confirmed case status to the NBR group. This allocation was guided by the confirmation rates observed among recipients of bivalent COVID-19 vaccines, as outlined by Xu et al.¹⁸ Five simulated datasets were generated to replicate the allocation process. SCCS analyses were conducted on each dataset, and the resulting estimates were aggregated using Rubin's rule,¹⁹ which accounts for both the variability within individual datasets and the variability across the multiple datasets.

Attributable risk (AR) was calculated using the approach described in Farrington et al. ²⁰: AR = $\left(\frac{RI-1}{RI}\right)\left(\frac{n_R}{N}\right)$ (1)

where RI is the relative incidence; n_R is the number of ischemic stroke events in the risk interval; and N is the number of recipients of a vaccine or dose. The reciprocal of AR is the number needed to harm (NNH).

Analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, North Carolina) and the SCCS models were fitted with the R package SCCS.²¹ This study was approved by KPSC Institutional Review Board. Patients or members of the public were not involved in the design, or conduct, or reporting, or dissemination plans of the research.

Results

Table 1 shows the characteristics of individuals who had ischemic stroke events. In total, there were 1057 ischemic stroke events among recipients of the Pfizer-BioNTech bivalent vaccine with a mean length of observation period of 204 days (ranging from 16 to 212 days), 827 ischemic stroke events among recipients of the Moderna bivalent vaccine with a mean length of observation period of 206 days (ranging from 31 to 212 days), and 3049 ischemic stroke events among NBR with a mean length of observation period of 197 days (ranging from 11 to 212 days). Notably, the majority of ischemic stroke events occurred among individuals \geq 65 years.

Risk of Ischemic Stroke Following the Pfizer-BioNTech Bivalent COVID-19 Vaccine

For the Pfizer-BioNTech bivalent COVID-19 vaccine, there were 103 electronically identified ischemic stroke events in the 21-day post-vaccination risk interval, 954 events in the control interval, and 3049 events among NBR; the overall RI was 0.90 (95% CI, 0.73–1.12) (eTable 2). The RI was not significantly above 1 across all subgroup

analyses by age, co-administration of influenza vaccine, and history of SARS-CoV-2 infection.

In analyses extending the risk interval to 1–42 days following bivalent vaccination, the overall RI was 0.97 (95% CI, 0.81–1.15) (Table 2). However, in subgroup analyses using the 1–42-day risk interval, we observed an increased risk of ischemic stroke only among individuals <65 years of age who also received an influenza vaccine on the same day. The RI in this subgroup was 2.14 (95% CI, 1.02–4.49). Among the subset who also had a documented history of SARS-CoV-2 infection within the year preceding the study period, the RI increased to 3.94 (95% CI, 1.10–14.16).

In this 1–42-day risk interval analysis of the specific subgroup of individuals aged <65 years who received bivalent and influenza vaccines on the same day, chart review of the 31 electronically identified ischemic stroke events found that 2 were determined to be hemorrhagic strokes, and 8 were subsequently found to not meet the criteria for true ischemic stroke events, yielding a confirmation rate of 68%. With the verified 21 ischemic stroke events and ischemic stroke events among NBR (not verified through chart review, but adjusted for using a 68% confirmation rate), we proceeded to reevaluate the RI in this subgroup. The number of confirmed ischemic stroke events was graphed over the interval in days between bivalent vaccination and ischemic stroke events in the control interval. Using a risk interval of 1–42 days after co-administration of the Pfizer-BioNTech bivalent vaccine and influenza vaccine, the overall RI derived from analyzing confirmed ischemic stroke events among those aged <65 years was 2.35 (95% CI, 0.98–5.65; P=.06) (Table 3). Between September 1, 2022 and March 31,

2023, 117,423 individuals aged <65 years received Pfizer-BioNTech bivalent vaccine and influenza vaccine on the same day. According to equation (1), $AR = 4.89 \times 10^{-5}$ and NNH = 20,440 with a risk interval of 1–42 days. Among 21,128 individuals who also had a documented history of SARS-CoV-2 infection within the year preceding the study period, the RI increased to 4.33 (95% CI, 0.98–19.11; *P*=.05) (Table 3); according to equation 1, $AR = 1.46 \times 10^{-4}$ and NNH = 6,868 with a risk interval of 1–42 days. Among the 10 confirmed ischemic stroke events in the risk interval of 1–42 days, the mean age was 58 years, ranging from 48 to 63 years. Among these cases, 2 individuals had a documented history of previous ischemic stroke, and no one died as of March 31, 2023. In addition, 7 received the standard dose, egg-based quadrivalent influenza vaccine, while 3 received an influenza vaccine of unknown formulation.

Risk of Ischemic Stroke Following the Moderna Bivalent COVID-19 Vaccine

When using a risk interval of 21 days following Moderna bivalent vaccination, the overall risk of ischemic stroke was not elevated from the analysis of electronically identified ischemic stroke events (RI=0.91; 95% CI, 0.71–1.15), a finding that held true across all subgroup analyses by age, co-administration of influenza vaccine, and history of SARS-CoV-2 infection (eTable 3). However, extending the risk interval to 42 days after Moderna bivalent vaccination showed an increased risk of ischemic stroke among individuals <65 years of age who had a documented history of SARS-CoV-2 infection, with an RI of 2.62 (95% CI, 1.13–6.03). This subgroup involved a total of 36 ischemic stroke events among recipients of the Moderna bivalent COVID-19 vaccine (Table 4).

Of the 36 ischemic stroke events, one was a hemorrhagic stroke and 12 were not confirmed as true events through medical chart review, yielding a confirmation rate of

64%. After using a risk interval of 1–42 days following the Moderna bivalent vaccination and applying a 64% confirmation rate to ischemic stroke events among NBR, the RI derived from analyzing confirmed ischemic stroke events among those aged <65 years who had a documented history of SARS-CoV-2 infection was 2.24 (95% CI, 0.78–6.47; P=.14).

Discussion

These SCCS analyses did not find evidence that the risk of ischemic stroke was elevated during the 1–21-day post-vaccination risk interval in both overall and subgroup analyses by age (<65 years versus ≥65 years), prior history of SARS-CoV-2 infection, and co-administration of influenza vaccine, for both Pfizer-BioNTech and Moderna bivalent vaccines. However, based on electronically identified events, the risk of ischemic stroke was increased within the 1–42-day window after vaccination among those aged <65 years who received their Pfizer-BioNTech bivalent vaccine and influenza vaccine on the same day; the risk was even higher among those who also had a documented SARS-CoV-2 infection history. After conducting chart review of ischemic stroke events, the point estimate for the risk of ischemic stroke was still elevated in a risk interval of 1–42 days for these two subgroup analyses, but did not meet the threshold for statistical significance (P=.06 and .05, respectively).

For Moderna bivalent vaccination, an initial increase in the risk of ischemic stroke emerged within the 1–42-day window after vaccination among those aged <65 years who had a documented SARS-CoV-2 infection history. However, after conducting chart review of ischemic stroke events, the relative incidence was 2.24 but was no longer statistically significantly elevated possibly due to a decreased sample size (P=.14).

Our study showed an increased point estimate for the risk of ischemic stroke in a risk interval of 1-42 days only among those aged <65 years who received their Pfizer-BioNTech bivalent vaccine and influenza vaccine on the same day, although not statistically significant. This finding is unique and may be attributed to differences in the study design compared to previous studies. First, our study employed a calendar-based observation period spanning from September 1, 2022, to March 31, 2023. This extended timeframe enabled us to use a longer risk window of 1-42 days following vaccination in addition to the risk interval of 1–21 days in previous studies. Second, we did not exclude individuals with a history of ischemic stroke, but we did apply criteria to increase the likelihood that ischemic stroke events during the study period represented a new ischemic stroke episode. Nevertheless, it is possible that there was interaction between bivalent vaccination and history of ischemic stroke. Furthermore, in subgroup analyses, we considered the influence of history of SARS-CoV-2 infection. SARS-CoV-2 infection is associated with an increased risk of ischemic stroke,^{15,16} and risk factors for SARS-CoV-2 infection may overlap with risk factors for ischemic stroke. There is potential interaction between bivalent vaccination and history of SARS-CoV-2 infection. The finding that the point estimate for the risk of ischemic stroke was elevated among individuals aged <65 years but not among individuals aged \geq 65 years is also biologically plausible. This may be due to the relatively heightened immune response and subsequent inflammation in the younger age group versus the older age group, and the fact that inflammation has been shown to be associated with an increased risk of ischemic stroke.^{22,23} Moreover, a smaller proportion of younger adults opted for bivalent

vaccination,²⁴ and those who did might have had a higher prevalence of comorbidities or poorer overall health status.

Limitations and Strengths

This study had several limitations. First, the study took place in a single health care system and thus the sample size was smaller than that of the VSD COVID-19 vaccine RCA. Additionally, the number of ischemic stroke events in individuals with a documented SARS-CoV-2 infection history who received co-administration of Pfizer-BioNTech bivalent vaccine and influenza vaccine was very small. This raises concerns about the validity of the asymptotic large sample assumptions that underlie both the 95% confidence intervals and P values. Second, we did not conduct chart review of ischemic stroke events among NBR; these events contributed to establishing baseline rates of ischemic stroke events during the study period. In addressing this issue, when analyzing chart-confirmed ischemic stroke events among recipients of bivalent vaccine, we applied the confirmation rate of ischemic stroke events among recipients of bivalent vaccine to ischemic stroke events among NBR. Moreover, we also did not undertake chart review of ischemic stroke events from those analyses when safety signals were absent. Third, while we excluded ischemic stroke events occurring within 30 days of SARS-CoV-2 infection, it is possible that some ischemic stroke events included in the analyses involved individuals with asymptomatic or mild COVID-19 disease who did not have a documented SARS-CoV-2 infection. Fourth, the elevated point estimate for the risk of ischemic stroke, while not statistically significant, was observed within the 1-42day period following co-administration of the Pfizer-BioNTech bivalent vaccine and influenza vaccine. This risk interval was longer than the 1–21 days or 1–28 days

investigated in earlier research.^{10,13,25} However, the biological plausibility for the occurrence of a vaccine-related ischemic stroke beyond 28 days remains uncertain. Fifth, unaccounted time-varying confounders could have also influenced the findings. Finally, our analysis did not adjust for multiple subgroup analyses by age, coadministration of bivalent COVID-19 vaccine and influenza vaccine, and history of SARS-CoV-2 infection. These specific subgroup analyses were pre-specified due to their potential safety concerns. The decision not to make multiple comparison adjustments was deliberate, aimed at ensuring that any potential vaccine safety concern could be detected.

The study also had several strengths. First, we addressed the impact of previous ischemic stroke events on bivalent COVID-19 vaccination by employing an event-dependent modified SCCS design. Second, we explored effect heterogeneity by conducting subgroup analyses based on factors such as age, documented history of SARS-CoV-2 infection, and co-administration of influenza vaccine. Third, to adjust for temporal trends, we included ischemic stroke events among NBR. This strategy not only enhanced the accuracy of estimating the baseline rate but also improved the statistical power for identifying potential safety signals. Finally, we re-analyzed ischemic stroke events that were confirmed through chart review for those analyses where safety signals were detected.

Future research should include several key aspects to further enhance the validity and robustness of our findings. Collaborative efforts with additional health care systems will enable us to significantly increase our sample size. A larger sample size could provide sufficient statistical power to conduct sensitivity analyses such as exclusion of

transient ischemic attack (TIA) and exclusion of those who had a history of ischemic stroke.

Conclusions

We found no evidence to suggest that the Pfizer-BioNTech bivalent vaccine increased the risk of ischemic stroke among individuals aged >65 years, consistent with the attenuated signal from the VSD surveillance that motivated this study. We found an elevated point estimate for the risk of ischemic stroke within 1–42 days (but not within 1-21 days) after the co-administration of the Pfizer-BioNTech bivalent vaccine and influenza vaccine among individuals <65 years old that did not reach statistical significance, although the sample size was limited. Future studies with a larger sample size are needed to evaluate the association between bivalent COVID-19 vaccination and ischemic stroke, as well as contributing factors such as history of SARS-CoV-2 infection. Any potential risks of ischemic stroke associated with bivalent COVID-19 vaccination must be balanced against the potential benefits of bivalent COVID-19 vaccination in preventing COVID-19-associated ischemic stroke and severe COVID-19 disease.

Conflict of Interest: LSS reports research support from Moderna for a COVID-19 vaccine effectiveness study and GlaxoSmithKline, Dynavax, and Moderna for unrelated studies. LQ reports research support from Moderna, GlaxoSmithKline, and Dynavax for unrelated studies. KB reports research support from Moderna, Pfizer, GlaxoSmithKline, and Dynavax for unrelated studies. NPK reports research support from Pfizer for COVID-19 vaccine clinical trials, and unrelated research support from Pfizer, GSK, Merck, and Sanofi Pasteur.

Funding/Support: Funding for this study was provided by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R01 Al168209.

Role of the Funder/Sponsor: The National Institutes of Health had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official views of the National Institutes of Health.

Additional Contributions: Kaiser Permanente Southern California stroke chart abstractions from the Vaccine Safety Datalink were used in this work. Kristin Goddard and Pat Ross from Kaiser Permanente Northern California and Kayla Hanson from Marshfield Clinic Research Institute developed the stroke chart abstraction forms. We thank the KPSC chart abstractors Jose Pio and Julliane Bacerdo.

REFERENCES

- 1. <u>https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use</u>. Accessed July 10, 2023.
- Rosenblum HG, Wallace M, Godfrey M, et al. Interim recommendations from the Advisory Committee on Immunization Practices for the use of bivalent booster doses of COVID-19 vaccines - United States, October 2022. MMWR Morb Mortal Wkly Rep. 2022 Nov 11;71(45):1436-1441.
- Chalkias S, Harper C, Vrbicky K, et al. A bivalent omicron-containing booster vaccine against Covid-19. N Engl J Med. 2022 Oct 6;387(14):1279-1291. doi: 10.1056/NEJMoa2208343. Epub 2022 Sep 16. PMID: 36112399; PMCID: PMC9511634.
- Davis-Gardner ME, Lai L, Wali B, et al. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA bivalent booster. New England J Med. 2023;388:183–185. doi:10.1056/NEJMc2214293
- Zou J, Kurhade C, Patel S, et al. Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent vaccine. N Engl J Med. 2023 Mar 2;388(9):854– 857. doi:10.1056/NEJMc2214916
- Hause AM, Marquez P, Zhang B, et al. Safety monitoring of bivalent COVID-19 mRNA vaccine booster doses among persons aged ≥12 Years - United States, August 31-October 23, 2022. MMWR Morb Mortal Wkly Rep. 2022 Nov 4;71(44):1401-1406.
- 7. Yih KW, Daley MF, Duffy J, et al. Safety signal identification for COVID-19 bivalent booster vaccination using tree-based scan statistics in the Vaccine Safety Datalink. VACCINE. 2023 August 14; 41(36):5265-5270.
- 8. Klein NP, Lewis N, Goddard K, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021 Oct 12;326(14):1390-1399.
- 9. https://www.fda.gov/media/164811/download. Accessed September 1, 2023.
- 10. <u>https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/cdc-and-fda-identify-preliminary-covid-19-vaccine-safety-signal-persons-aged-65-years-and-older.</u> Accessed August 1, 2023.
- 11. ACIP. https://stacks.cdc.gov/view/cdc/127294. Accessed 8/10/2023.
- Gorenflo MP, Davis PB, Kaelber DC, Xu R. Ischemic stroke after COVID-19 bivalent vaccine administration in patients aged 65 years and older: analysis of nation-wide patient electronic health records in the United States. medRxiv [Preprint]. 2023 Feb 14:2023.02.11.23285801. doi: 10.1101/2023.02.11.23285801
- Jabagi MJ, Bertrand M, Botton J, et al. Stroke, myocardial infarction, and pulmonary embolism after bivalent booster. N Engl J Med. 2023;388(15):1431-1432.
- Ghebremichael-Weldeselassie Y, Jabagi MJ, Botton J, et al. A modified selfcontrolled case series method for event-dependent exposures and high eventrelated mortality, with application to COVID-19 vaccine safety. Stat Med. 2022 May 10;41(10):1735-1750.

- 15. Merkler AE, Parikh NS, Mir S, et al. Risk of ischemic stroke in patients with Coronavirus Disease 2019 (COVID-19) vs patients with influenza. JAMA Neurol. 2020;77(11):1366–1372.
- 16. Yang Q, Tong X, George MG, Chang A, Merritt RK. COVID-19 and risk of acute ischemic stroke among medicare beneficiaries aged 65 years or older: self-controlled case series study. Neurology. 2022 Feb 22;98(8):e778-e789.
- 17. Farrington CP, Whitaker HJ, Hocine MN. Case series analysis for censored, perturbed, or curtailed post-event exposures. Biostatistics. 2009;10:3–16.
- 18. Xu S, Clarke CL, Newcomer SR, Daley MF, Glanz JM. Analyzing self-controlled case series data when case confirmation rates are estimated from an internal validation sample. Biom J [Biometrische Zeitschrift]. 2018;60(4):748-760.
- 19. Rubin DB. Multiple imputation for nonresponse in surveys. New York: John Wiley and Sons; 2004.
- Farrington P, Whitaker H, Ghebremichael-Weldeselassie Y. Self-controlled event series studies: A modelling guide with R. Boca Raton, FL: Chapman & Hall/CRC Press; 2018.
- 21. Ghebremichael-Weldeselassie Y, Whitaker, H, Farrington P. SCCS: the selfcontrolled case series method. R package version 1.4. https://CRAN.Rproject.org/package=SCCS. Accessed January 13, 2023.
- Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol. 2010 May;87(5):779-89. doi: 10.1189/jlb.1109766.
- 23. Brockman MA, Mwimanzi F, Lapointe HR, et al. Reduced magnitude and durability of humoral immune responses to COVID-19 mRNA vaccines among older adults. The Journal of Infectious Diseases. 2022; 225:129–1140.
- 24. https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-boosterpercent-total. Accessed August 22, 2023
- 25. Ihle-Hansen H, Bøås H, Tapia G, et al. Stroke after SARS-CoV-2 mRNA vaccine: a nationwide registry study. Stroke. 2023 May;54(5):e190-e193.

SUPPLEMENT

eTable 1. Definition of Electronically Identified Ischemic Strokes.

eTable 2. Numbers of Electronically Identified Ischemic Stroke Events and Relative Incidences in the 21 Days after Pfizer-BioNTech Bivalent COVID-19 Vaccination

eTable 3. Numbers of Electronically Identified Ischemic Stroke Events and Relative Incidences in the 21 Days after Moderna Bivalent COVID-19 Vaccination

BioNTech bivalent COVID- 19 vaccine, no. (%) bivalent COVID- vaccine, no. (%) bivalent vaccines, no. (%) Overall 1057 (100.0) 827 (100.0) 3049 (100.0) Age (in years) - - - 12-17 1 (0.1) N/A 6 (0.2) 18-44 32 (3.0) 15 (1.8) 261 (8.6) 45-64 245 (23.2) 177 (21.4) 1011 (33.2) 65-74 618 (58.5) 501 (60.6) 1406 (46.1) 75+ 161 (15.2) 134 (16.2) 365 (12.0) Sex - - - Female 540 (51.1) 446 (53.9) 1637 (53.7) Male 517 (48.9) 381 (46.1) 1412(46.3) Race/ethnicity - - - Hispanic 311 (29.4) 259 (31.3) 1186 (38.9) Non-Hispanic Asian 119 (11.3) 99 (12.0) 270 (8.9) Non-Hispanic Black 139 (13.1) 120 (14.5) 472 (15.5) Missing 6 (0.6) 9 (1.1) 37 (1.2) <th></th> <th>Recipients of Pfizer -</th> <th>Recipients of Moderna</th> <th>Non-recipients of</th>		Recipients of Pfizer -	Recipients of Moderna	Non-recipients of
19 vaccine, no. (%) vaccine, no. (%) no. (%) Overall 1057 (100.0) 827 (100.0) 3049 (100.0) Age (in years) - - - 12-17 1 (0.1) N/A 6 (0.2) 18-44 32 (3.0) 15 (1.8) 261 (8.6) 45-64 245 (23.2) 177 (21.4) 1011 (33.2) 65-74 618 (58.5) 501 (60.6) 1406 (46.1) 75+ 161 (15.2) 134 (16.2) 365 (12.0) Sex - - - Female 540 (51.1) 446 (53.9) 1637 (53.7) Male 517 (48.9) 381 (46.1) 1412(46.3) Race/ethnicity - - - Hispanic 311 (29.4) 259 (31.3) 1186 (38.9) Non-Hispanic White 470 (44.5) 326 (39.4) 1027 (33.7) Non-Hispanic Asian 119 (11.3) 99 (12.0) 270 (8.9) Non-Hispanic Black 139 (13.1) 120 (14.5) 472 (15.5) Missing 6 (0.6) 9		BioNTech bivalent COVID-	bivalent COVID-19	bivalent vaccines,
Overall 1057 (100.0) 827 (100.0) 3049 (100.0) Age (in years) 1		19 vaccine, no. (%)	vaccine, no. (%)	no. (%)
Age (in years) Image: mail of the system N/A 6 (0.2) 12-17 1 (0.1) N/A 6 (0.2) 18-44 32 (3.0) 15 (1.8) 261 (8.6) 45-64 245 (23.2) 177 (21.4) 1011 (33.2) 65-74 618 (58.5) 501 (60.6) 1406 (46.1) 75+ 161 (15.2) 134 (16.2) 365 (12.0) Sex - - - Female 540 (51.1) 446 (53.9) 1637 (53.7) Male 517 (48.9) 381 (46.1) 1412 (46.3) Race/ethnicity - - - Hispanic 311 (29.4) 259 (31.3) 1186 (38.9) Non-Hispanic Asian 119 (11.3) 99 (12.0) 270 (8.9) Non-Hispanic Black 139 (13.1) 120 (14.5) 472 (15.5) Missing 6 (0.6) 9 (1.1) 37 (1.2)	Overall	1057 (100.0)	827 (100.0)	3049 (100.0)
12-17 1 (0.1) N/A 6 (0.2) 18-44 32 (3.0) 15 (1.8) 261 (8.6) 45-64 245 (23.2) 177 (21.4) 1011 (33.2) 65-74 618 (58.5) 501 (60.6) 1406 (46.1) 75+ 161 (15.2) 134 (16.2) 365 (12.0) Sex	Age (in years)			
18-44 32 (3.0) 15 (1.8) 261 (8.6) 45-64 245 (23.2) 177 (21.4) 1011 (33.2) 65-74 618 (58.5) 501 (60.6) 1406 (46.1) 75+ 161 (15.2) 134 (16.2) 365 (12.0) Sex - - - Female 540 (51.1) 446 (53.9) 1637 (53.7) Male 517 (48.9) 381 (46.1) 1412(46.3) Race/ethnicity - - - Hispanic 311 (29.4) 259 (31.3) 1186 (38.9) Non-Hispanic White 470 (44.5) 326 (39.4) 1027 (33.7) Non-Hispanic Black 139 (13.1) 120 (14.5) 472 (15.5) Missing 6 (0.6) 9 (1.1) 37 (1.2)	12-17	1 (0.1)	N/A	6 (0.2)
45-64245 (23.2)177 (21.4)1011 (33.2)65-74618 (58.5)501 (60.6)1406 (46.1)75+161 (15.2)134 (16.2)365 (12.0)SexFemale540 (51.1)446 (53.9)1637 (53.7)Male517 (48.9)381 (46.1)1412(46.3)Race/ethnicityHispanic311 (29.4)259 (31.3)1186 (38.9)Non-Hispanic White470 (44.5)326 (39.4)1027 (33.7)Non-Hispanic Black139 (13.1)120 (14.5)472 (15.5)Missing6 (0.6)9 (1.1)37 (1.2)Maining Content of the section of the	18-44	32 (3.0)	15 (1.8)	261 (8.6)
65-74 618 (58.5) 501 (60.6) 1406 (46.1) 75+ 161 (15.2) 134 (16.2) 365 (12.0) Sex	45-64	245 (23.2)	177 (21.4)	1011 (33.2)
75+ 161 (15.2) 134 (16.2) 365 (12.0) Sex Female 540 (51.1) 446 (53.9) 1637 (53.7) Male 517 (48.9) 381 (46.1) 1412(46.3) Race/ethnicity Hispanic 311 (29.4) 259 (31.3) 1186 (38.9) Non-Hispanic White 470 (44.5) 326 (39.4) 1027 (33.7) Non-Hispanic Asian 119 (11.3) 99 (12.0) 270 (8.9) Non-Hispanic Black 139 (13.1) 120 (14.5) 472 (15.5) Missing 6 (0.6) 9 (1.1) 37 (1.2)	65-74	618 (58.5)	501 (60.6)	1406 (46.1)
Sex Image: Sex Sex Image: Sex Sex Image: Sex Sex <thsex< th=""> <thsex< th=""> Sex</thsex<></thsex<>	75+	161 (15.2)	134 (16.2)	365 (12.0)
Female540 (51.1)446 (53.9)1637 (53.7)Male517 (48.9)381 (46.1)1412(46.3)Race/ethnicity259 (31.3)1186 (38.9)Hispanic311 (29.4)259 (31.3)1186 (38.9)Non-Hispanic White470 (44.5)326 (39.4)1027 (33.7)Non-Hispanic Asian119 (11.3)99 (12.0)270 (8.9)Non-Hispanic Black139 (13.1)120 (14.5)472 (15.5)Missing6 (0.6)9 (1.1)37 (1.2)	Sex			
Male517 (48.9)381 (46.1)1412(46.3)Race/ethnicityHispanic311 (29.4)259 (31.3)1186 (38.9)Non-Hispanic White470 (44.5)326 (39.4)1027 (33.7)Non-Hispanic Asian119 (11.3)99 (12.0)270 (8.9)Non-Hispanic Black139 (13.1)120 (14.5)472 (15.5)Missing6 (0.6)9 (1.1)37 (1.2)	Female	540 (51.1)	446 (53.9)	1637 (53.7)
Race/ethnicity Image: Marcologic line State	Male	517 (48.9)	381 (46.1)	1412(46.3)
Hispanic311 (29.4)259 (31.3)1186 (38.9)Non-Hispanic White470 (44.5)326 (39.4)1027 (33.7)Non-Hispanic Asian119 (11.3)99 (12.0)270 (8.9)Non-Hispanic Black139 (13.1)120 (14.5)472 (15.5)Missing6 (0.6)9 (1.1)37 (1.2)Multiple (2010)400 (4.4)44.470	Race/ethnicity			
Non-Hispanic White470 (44.5)326 (39.4)1027 (33.7)Non-Hispanic Asian119 (11.3)99 (12.0)270 (8.9)Non-Hispanic Black139 (13.1)120 (14.5)472 (15.5)Missing6 (0.6)9 (1.1)37 (1.2)Mathink (2)40 (4.4)44 (4.7)57 (4.0)	Hispanic	311 (29.4)	259 (31.3)	1186 (38.9)
Non-Hispanic Asian 119 (11.3) 99 (12.0) 270 (8.9) Non-Hispanic Black 139 (13.1) 120 (14.5) 472 (15.5) Missing 6 (0.6) 9 (1.1) 37 (1.2)	Non-Hispanic White	470 (44.5)	326 (39.4)	1027 (33.7)
Non-Hispanic Black 139 (13.1) 120 (14.5) 472 (15.5) Missing 6 (0.6) 9 (1.1) 37 (1.2) Multiple (21) 42 (14.2) 57 (1.2)	Non-Hispanic Asian	119 (11.3)	99 (12.0)	270 (8.9)
Missing 6 (0.6) 9 (1.1) 37 (1.2) Mathina (21) 40 (4.4) 57 (4.2)	Non-Hispanic Black	139 (13.1)	120 (14.5)	472 (15.5)
	Missing	6 (0.6)	9 (1.1)	37 (1.2)
Multiple/Other 12 (1.1) 14 (1.7) 57 (1.9)	Multiple/Other	12 (1.1)	14 (1.7)	57 (1.9)
Length of observation 204.3 (26.8) 205.7 (23.5) 196.7 (39.9)	Length of observation	204.3 (26.8)	205.7 (23.5)	196.7 (39.9)
period in days, mean (SD)	period in days, mean (SD)			
Death 50 (4.7) 37 (4.5) 309 (10.1)	Death	50 (4.7)	37 (4.5)	309 (10.1)

Table 1. Characteristics of Individuals Who Had Ischemic Stroke Events during the Period from

 September 1, 2022 to March 31, 2023

SD, standard deviation

Table 2. Numbers of Electronically Identified Ischemic Stroke Events and Relative Incidences in the 42 Days after Pfizer-BioNTech Bivalent

 COVID-19 Vaccination

	1		A 11											
	All ages					<65 years old					265 years old			
	Nun	nber of eve	ents		Nun	Number of events				nber of eve	ents			
	Risk	Control	NBR [§]	Relative	Risk	Control	NBR [§]	Relative incidence	Risk	Control	NBR [§]	Relative		
	interval	interval		incidence (95%	interval	interval		(95% CI)	interval	interval		incidence (95%		
				CI)				,				CI)		
Overall	212	845	3049	0.97 (0.81–1.15)	50	228	1278	0.98 (0.69-1.38)	162	617	1771	0.96 (0.79–1.17)		
With history of SARS-CoV-2	35	139	565	0.98 (0.66–1.47)	15	53	292	1.22 (0.64–2.33)	20	86	273	0.83 (0.50-1.40)		
Without history of SARS-CoV-2	177	706	2484	0.97 (0.80–1.17)	35	175	986	0.91 (0.61–1.38)	142	531	1498	0.99 (0.80-1.22)		
Co-administration of influenza	41	106	3049	0.99 (0.68–1.45)	15	16	1278	2.14 (1.02–4.49)	26	90	1771	0.77 (0.49–1.23)		
vaccine, overall														
With history of SARS-CoV-2	9	18	565	1.36 (0.61-3.05)	6	4	292	3.94 (1.10–14.16)	3	14	273	0.58 (0.16-2.14)		
Without history of SARS-CoV-2	32	88	2484	0.92 (0.60–1.41)	9	12	986	1.58 (0.61-4.09)	23	76	1498	0.81 (0.49–1.33)		
No co-administration of	171	739	3049	0.95 (0.79–1.16)	35	212	1278	0.80 (0.54–1.19)	136	527	1771	1.00 (0.81–1.24)		
influenza vaccine, overall														
With history of SARS-CoV-2	26	121	565	0.87 (0.55–1.38)	9	49	292	0.82 (0.37-1.80)	17	72	273	0.85 (0.49-1.50)		
Without history of SARS-CoV-2	145	618	2484	0.98 (0.80-1.21)	26	163	986	0.81 (0.51-1.28)	119	455	1498	1.03 (0.81-1.30)		

^SNon-bivalent recipients (NBR) were eligible individuals who did not receive a bivalent vaccine but had completed a primary series of COVID-19 vaccination and had their last monovalent dose ≥60 days before 9/1/2022. Inclusion of these events helps to adjust for temporal trends (seasonality). The same NBR population was used in overall bivalent analyses as well as bivalent analyses stratified by co-administration of influenza vaccine. [□] Had SARS-CoV-2 infection (i.e., SARS-CoV-2 positive laboratory test or a COVID-19 diagnosis) during the year prior (08/31/2021-08/31/2022).

Table 3. Numbers of Confirmed Ischemic Stroke Events among Recipients of the Pfizer-BioNTech Bivalent COVID-19 Vaccine Aged <65 years, and Relative Incidences in the 42 Days after Co-administration of Bivalent and Influenza Vaccines

		Number of events		
	Risk interval	Control interval	Relative incidence (95% CI)	
Co-administration of influenza vaccine, overall	10	11	874	2.35 (0.98–5.65)
With history of SARS-CoV-2	4	3	197	4.33 (0.98–19.11)
Without history of SARS-CoV-2	6	8	677	1.76 (0.57–5.42)

[§]Non-bivalent recipients (NBR) were eligible individuals who did not receive a bivalent vaccine but had completed a primary series of COVID-19 vaccination and had their last monovalent dose ≥60 days before 9/1/2022. Inclusion of these events helps to adjust for temporal trends (seasonality). A confirmation rate of 68% was applied to ischemic stroke events among NBR.

¹Had SARS-CoV-2 infection (i.e., SARS-CoV-2 positive laboratory test or a COVID-19 diagnosis) during the year prior (08/31/2021-08/31/2022).

Vaccination												
			All ages	6		<	65 years	old	≥65 years old			
	Nun	nber of eve	ents		Nun	nber of eve	ents		Number of events			
	Risk	Control	NBR [§]	Relative	Risk C		NBR [§]	Relative incidence	Risk Control	NBR [§]	Relative	
	interval	interval		incidence (95%	interval	interval		(95% CI)	interval	interval		incidence (95%
				CI)								CI)
Overall	161	666	3049	0.92 (0.76-1.12)	34	158	1278	0.99 (0.64–1.53)	127	508	1771	0.90 (0.72–1.13)
With history of SARS-CoV-2	28	111	565	1.02 (0.66-1.59)	10	26	292	2.62 (1.13-6.03)	18	85	273	0.71 (0.42–1.19)
Without history of SARS-CoV-2	133	555	2484	0.90 (0.72-1.12)	24	132	986	0.73 (0.43-1.23)	109	423	1498	0.95 (0.74–1.21)
Co-administration of influenza	20	55	3049	0.80 (0.45–1.40)	8	15	1278	1.33 (0.56–3.18)	12	40	1771	0.64 (0.31–1.31)
vaccine, overall												
With history of SARS-CoV-2	3	14	565	0.51 (0.14–1.93)	3	4	292	2.43 (0.54–10.87)	0	10	273	NA
Without history of SARS-CoV-2	17	41	2484	0.89 (0.48-1.66)	5	11	986	0.96 (0.33-2.80)	12	30	1498	0.88 (0.41–1.88)
No co-administration of	141	611	3049	0.93 (0.76–1.15)	26	143	1278	0.90 (0.55–1.49)	115	468	1771	0.94 (0.74–1.18)
influenza vaccine, overall												
With history of SARS-CoV-2	25	97	565	1.14 (0.71–1.82)	7	22	292	2.69 (0.98–7.36)	18	75	273	0.85 (0.49–1.46)
Without history of SARS-CoV-2	116	514	2484	0.90(0.71 - 1.14)	19	121	986	0.68(0.37 - 1.23)	97	393	1498	0.96(0.74-1.24)

Table 4. Numbers of Electronically Identified Ischemic Stroke Events and Relative Incidences in the 42 Days after Moderna Bivalent COVID-19

 Vaccination

[§]Non-bivalent recipients (NBR) were eligible individuals who did not receive a bivalent vaccine but had completed a primary series of COVID-19 vaccination and had their last monovalent dose ≥60 days before 9/1/2022. Inclusion of these events helps to adjust for temporal trends (seasonality). The same NBR population was used in overall bivalent analyses as well as bivalent analyses stratified by co-administration of influenza vaccine. [□]Had SARS-CoV-2 infection (i.e., SARS-CoV-2 positive laboratory test or a COVID-19 diagnosis) during the year prior (08/31/2021-08/31/2022).

Figure 1. Number of Confirmed Ischemic Stroke Events over the Interval in Days between Bivalent Vaccination and Ischemic Stroke Event among Those Who Received Pfizer-BioNTech Bivalent Vaccine and Influenza Vaccine on the Same Day



Supplement

eTable 1. Definition of Electronically Identified Ischemic Strokes.

Incident ischemic stroke in emergency department or inpatient settings		Adjust is ICD-10 cc prior to t	chemic stroke onset if the ode occurred in the 1 day he incident case in all settings	Exclude cases du possible ICD-10 c the time prior to t (not incl day) in a	ischemic stroke ue to other causes if the ode occurred in period noted the incident case uding the same ill settings	Exclude ischemic stroke cases due to other possible causes if the ICD-10 code occurred on the same day as the incident case			
ICD-10	Description	ICD-10	Description	ICD-10	Description	ICD-10	Description		
G45.8	Other transient cerebral ischemic attacks and related syndromes	Z92.82	Status post administration of tPA (rtPA) in a different facility within the last 24 hours prior to admission to current facility	148.*	Atrial fibrillation and flutter (if seen ever prior to the incident case)	S15.*	Injury of blood vessels at neck level		
G45.9	Transient cerebral ischemic attack, unspecified	R51.*	Headache	l21.*	Acute myocardial infarction (if seen within 28 days prior to the incident case)	174.*	Arterial embolism and thrombosis		
163.*	Cerebral infarction	R47.*	Speech disturbances, not elsewhere classified	S15.*	Injury of blood vessels at neck level (if seen within 1 day prior to the incident case)	Physical Footnote	trauma codes - see e A		
		R29.810	Facial weakness	174.*	Arterial embolism and thrombosis (if seen within 1 day prior to the incident case)				
		R53.1	Weakness	D57.*	Sickle-cell disorders (if seen EVER prior to the incident case)				
	R42.*		Dizziness and giddiness	D68.5*	Primary thrombophilia (if seen EVER prior to the incident case)				
		R41.82	Altered mental status, unspecified	Exclude infection ⁹ last 30 da incident o same day	if SARS-CoV2 cocurred in the ays prior to the case (not including y)				
		R40.4	Transient alternation of awareness						
		G81.9*	Hemiplegia, unspecified						
		H53.9	Unspecified visual disturbance						
		H53.13*	Sudden visual loss						

*=any remaining characters; ^{\$}SARS-CoV-2 positive laboratory test or a COVID-19 diagnosis.

Trauma - ex	Footnote A: Physical Trauma Codes ternal causes of morbidity (V00-Y99):
V00-V09	Pedestrian injured in transport accident
V10-V19	Pedal cycle rider injured in transport accident
V20-V29	Motorcycle rider injured in transport accident
V30-V39	Occupant of three-wheeled motor vehicle injured in transport accident
V40-V49	Car occupant injured in transport accident
V50-V59	Occupant of pick-up truck or van injured in transport accident
V60-V69	Occupant of heavy transport vehicle injured in transport accident
V70-V79	Bus occupant injured in transport accident
V80-V89	Other land transport accidents
V90-V94	Water transport accidents
V95-V97	Air and space transport accidents
V98-V99	Other and unspecified transport accidents
W00-W19	Slipping, tripping, stumbling and falls
W20-W49	Exposure to inanimate mechanical forces
W50-W64	Exposure to animate mechanical forces
W65-W74	Accidental non-transport drowning and submersion
W85-W99	Exposure to electric current, radiation and extreme ambient air temperature and pressure
X00-X08	Exposure to smoke, fire and flames
X10-X19	Contact with heat and hot substances
X30-X39	Exposure to forces of nature
X50.*	Overexertion and strenuous or repetitive movements
X52-X58	Accidental exposure to other specified factors
X71-X83	Intentional self-harm
X92-Y09	Assault
Y21-Y33	Event of undetermined intent
Y35-Y38	Legal intervention, operations of war, military operations, and terrorism
Y62-Y69	Misadventures to patients during surgical and medical care
Y70-Y82	Medical devices associated with adverse incidents in diagnostic and therapeutic use
Y83-Y84	Surgical and other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
Y90-Y99	Supplementary factors related to causes of morbidity classified elsewhere

eTable 2. Numbers of Electronically Identified Ischemic Stroke Events and Relative Incidences in the 21 Days after Pfizer-BioNTech Bivalent
COVID-19 Vaccination.

	All ages					<65 years old				≥65 years old				
	Nun	Number of events				nber of eve	ents		Nun	nber of e				
	Risk interval	Control interval	NBR§	Relative incidence (95% CI)	Risk interval	Control interval	NBR [§]	Relative incidence (95% CI)	Risk interval	Contr ol interv al	NBR [§]	Relative incidence (95% CI)		
Overall	103	954	3049	0.90 (0.73–1.12)	19	259	1278	0.68 (0.42-1.12)	84	695	1771	0.98 (0.77-1.25)		
With history of SARS-CoV-2	12	162	565	0.68 (0.39–1.19)	2	66	292	0.52 (0.18–1.51)	10	96	273	0.77 (0.40–1.47)		
Without history of SARS-CoV-2	91	792	2484	0.96 (0.76–1.21)	17	193	986	0.75 (0.43–1.32)	74	599	1498	1.02 (0.79–1.33)		
Co-administration of influenza	22	125	3049	1.03 (0.65–1.62)	6	25	1278	1.39 (0.60–3.24)	16	100	1771	0.94 (0.55–1.62)		
vaccine, overall														
With history of SARS-CoV-2	3	24	565	0.85 (0.31-2.29)	1	9	292	1.35 (0.33–5.52)	2	15	273	0.61 (0.16–2.35)		
Without history of SARS-CoV-2	19	101	2484	1.07 (0.65–1.79)	5	16	986	1.41 (0.49–4.02)	14	85	1498	1.02 (0.56–1.83)		
No co-administration of	81	829	3049	0.87 (0.68–1.11)	13	234	1278	0.55 (0.30-1.01)	68	595	1771	0.97 (0.75–1.27)		
influenza vaccine, overall														
With history of SARS-CoV-2	9	138	565	0.63 (0.32-1.22)	1	57	292	0.33 (0.07-1.50)	8	81	273	0.78 (0.37-1.62)		
Without history of SARS-CoV-2	72	691	2484	0.93(0.71 - 1.20)	12	177	986	0.64(0.33 - 1.24)	60	514	1498	1.01(0.76 - 1.35)		

⁸Non-bivalent recipients (NBR) were eligible individuals who did not receive a bivalent vaccine but had completed a primary series of COVID-19 vaccination and had their last monovalent dose \geq 60 days before 9/1/2022. Inclusion of these events helps to adjust for temporal trends (seasonality). The same NBR population was used in overall bivalent analyses as well as bivalent analyses stratified by co-administration of influenza vaccine. ^{\Box} Had SARS-CoV-2 infection (i.e., SARS-CoV-2 positive laboratory test or a COVID-19 diagnosis) during the year prior (08/31/2021-08/31/2022).

Vaccination													
			All ages	;		<6	5 years	old		≥65 years old			
	Nun	nber of eve	ents		Nun	Number of events				nber of eve	ents		
	Risk interval	Control interval	NBR [§]	Relative incidence (95% CI)	Risk interval	Control interval	NBR [§]	Relative incidence (95% CI)	Risk interval	Control interval	NBR [§]	Relative incidence (95% CI)	
Overall	82	745	3049	0.91 (0.71–1.15)	13	179	1278	0.63 (0.35–1.14)	69	566	1771	0.99 (0.76–1.29)	
With history of SARS-CoV-2	10	129	565	0.60 (0.32-1.14)	3	33	292	0.87 (0.25-2.97)	7	96	273	0.52 (0.25–1.10)	
Without history of SARS-CoV-2	72	616	2484	0.98 (0.75–1.28)	10	146	986	0.58 (0.30-1.13)	62	470	1498	1.11 (0.83–1.47)	
Co-administration of influenza	8	67	3049	0.59 (0.27–1.28)	4	19	1278	1.10 (0.37–3.21)	4	48	1771	0.42 (0.14–1.27)	
vaccine, overall													
With history of SARS-CoV-2	1	16	565	0.34 (0.04–2.67)	1	6	292	1.03 (0.12-8.79)	0	10	273	N/A	
Without history of SARS-CoV-2	7	51	2484	0.65 (0.28-1.54)	3	13	986	1.07 (0.31-3.63)	4	38	1498	0.52 (0.16-1.67)	
No co-administration of	74	678	3049	0.95 (0.74–1.23)	9	160	1278	0.53 (0.27–1.07)	65	518	1771	1.07 (0.81–1.41)	
influenza vaccine, overall													
With history of SARS-CoV-2	9	113	565	0.64 (0.33–125)	2	27	292	0.79 (0.18–3.54)	7	86	273	0.59 (0.28–1.24)	
Without history of SARS-CoV-2	65	565	2484	1.03(0.78 - 1.35)	7	133	986	0.49(0.22 - 1.07)	58	432	1498	1.19(0.89 - 1.60)	

eTable 3. Numbers of Electronically Identified Ischemic Stroke Events and Relative Incidences in the 21 Days after Moderna Bivalent COVID-19 Vaccination

[§]Non-bivalent recipients (NBR) were eligible individuals who did not receive a bivalent vaccine but had completed a primary series of COVID-19 vaccination and had their last monovalent dose ≥60 days before 9/1/2022. Inclusion of these events helps to adjust for temporal trends (seasonality). The same NBR population was used in overall bivalent analyses as well as bivalent analyses stratified by co-administration of influenza vaccine. [□] Had SARS-CoV-2 infection (i.e., SARS-CoV-2 positive laboratory test or a COVID-19 diagnosis) during the year prior (08/31/2021-08/31/2022).